PHARMAID

Pharmaids Pharmaceuticals financials

Market cap
₹106 Cr

Quarterly results

Q1 FY27: revenue down 100.0%, net profit up 148.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1 1 0 1 6 +619%1 −31%3 +1969%0 −100%
EBITDA-1 -2 -3 -5 -5 −302%-4 −112%-1 +60%-1 +82%
Net profit-1 -2 -3 -4 -2 −63%-3 −96%-1 +57%2 +149%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −49.3% 1Y

₹30.0₹40.0₹50.0₹60.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹59.93 on 10 Sept 2025 → ₹30.39. High ₹60.98 (26 Sept 2025), low ₹26.9 (1 Jun 2026).

Financials, as filed

Revenue grew 1780.6% a year over 2 years, FY24 to FY26. Operating margin widened to -133.9%.

Year endingFY24FY25FY26
Revenue₹0 Cr₹2 Cr₹11 Cr
Operating profit₹-7 Cr₹-7 Cr₹-14 Cr
Operating margin-22866.7%-311.1%-133.9%
Interest₹0 Cr₹2 Cr₹3 Cr
Depreciation₹0 Cr₹0 Cr₹0 Cr
Net profit₹-5 Cr₹-7 Cr₹-10 Cr
Net margin-17300.0%-311.1%-98.3%
Cash from operations₹-3 Cr₹-8 Cr₹-4 Cr
Free cash flow₹-20 Cr₹-17 Cr₹14 Cr
ROCE-10.8%-7.0%-15.8%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY22FY23FY24FY25FY26
Equity capital₹10 Cr₹21 Cr₹35 Cr₹35 Cr₹35 Cr
Reserves₹-2 Cr₹1 Cr₹36 Cr₹17 Cr₹18 Cr
Borrowings₹0 Cr₹0 Cr₹13 Cr₹20 Cr₹21 Cr
Other liabilities₹2 Cr₹2 Cr₹1 Cr₹26 Cr₹10 Cr
Total liabilities₹11 Cr₹25 Cr₹85 Cr₹98 Cr₹84 Cr
Fixed assets₹0 Cr₹0 Cr₹17 Cr₹55 Cr₹8 Cr
Capital work in progress₹0 Cr₹2 Cr₹2 Cr₹3 Cr₹5 Cr
Investments₹0 Cr₹3 Cr₹53 Cr₹0 Cr₹53 Cr
Other assets₹11 Cr₹19 Cr₹14 Cr₹41 Cr₹18 Cr
Total assets₹11 Cr₹25 Cr₹85 Cr₹98 Cr₹84 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters added +27.85 pp while the public trimmed −27.85 pp. The shareholder count grew 8% to 8,632.

Promoters
33.0%
Public
67.0%

Since Jun 2025

  • Promoters +27.85 pp
  • Public −27.85 pp

How it drifted, 12 quarters

Over this window promoters went from 9.7% to 33.0% — +23.3 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 9.7%, Public 90.3%.Dec '23: Promoters 9.3%, Public 90.8%.Mar '24: Promoters 5.6%, Public 94.4%.Jun '24: Promoters 5.6%, Public 94.4%.Sep '24: Promoters 5.2%, Public 94.8%.Dec '24: Promoters 5.2%, Public 94.8%.Mar '25: Promoters 5.2%, Public 94.8%.Jun '25: Promoters 5.1%, Public 94.9%.Sep '25: Promoters 33.0%, Public 67.0%.Dec '25: Promoters 33.0%, Public 67.0%.Mar '26: Promoters 33.0%, Public 67.0%.Jun '26: Promoters 33.0%, Public 67.0%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Pharmaids Pharmaceuticals Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Shankarappa Nagaraja Vinaya Babu 28.52%unchanged
Shreedhara Shetty 14.53%unchanged
Gokaram Ramkrishna Balaji 7.99%unchanged
Smitha Shetty Sachit Shetty 7.72%unchanged
Tumkur Trade Center Private Limited 4.45%unchanged
Venkata Rao Sadhanala 4.32%unchanged
Makam Sreevalli 2.21%unchanged
Venu Madhava Kaparthy 2.03%unchanged
Venkatesh Mahendra 1.24%unchanged
Kant Rao 0.02%unchanged
Activin Chemicals and Pharmaceuticals Private Limited 0.00%unchanged
Koye Lifesciences Private Limited 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Pharmaids Pharmaceuticals Ltd.

Guides on how to read this kind of business and the numbers that matter.